WO2002074289A2 - Antitumor compositions containing taxane derivatives - Google Patents

Antitumor compositions containing taxane derivatives Download PDF

Info

Publication number
WO2002074289A2
WO2002074289A2 PCT/IB2002/000853 IB0200853W WO02074289A2 WO 2002074289 A2 WO2002074289 A2 WO 2002074289A2 IB 0200853 W IB0200853 W IB 0200853W WO 02074289 A2 WO02074289 A2 WO 02074289A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
constituents
composition
neoplastic disease
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2002/000853
Other languages
English (en)
French (fr)
Other versions
WO2002074289A3 (en
Inventor
Marie-Christine Bissery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200301047A priority Critical patent/EA006878B1/ru
Priority to BR0208274-8A priority patent/BR0208274A/pt
Priority to EP02713093A priority patent/EP1478355B1/en
Priority to CA2440160A priority patent/CA2440160C/en
Priority to DK02713093T priority patent/DK1478355T3/da
Priority to AU2002244877A priority patent/AU2002244877B2/en
Priority to SI200230525T priority patent/SI1478355T1/sl
Priority to MXPA03008539A priority patent/MXPA03008539A/es
Priority to JP2002572997A priority patent/JP4467885B2/ja
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to DE60218751T priority patent/DE60218751T2/de
Priority to HU0500478A priority patent/HUP0500478A2/hu
Publication of WO2002074289A2 publication Critical patent/WO2002074289A2/en
Priority to IL157992A priority patent/IL157992A/en
Anticipated expiration legal-status Critical
Publication of WO2002074289A3 publication Critical patent/WO2002074289A3/en
Priority to CY20071100643T priority patent/CY1106582T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to combinations of taxol, Taxotere and their
  • Taxol Taxol, Taxotere and their analogues, which possess noteworthy antitumor
  • subject to be treated are between 1 and 10 mg/kg administered intraperitoneally
  • agents such as cyclophosphamide, isosfamide, melphalan, hexametyl-
  • analogues for instance 5-fluarouracil and cytarabine, or its analogues such as 2-
  • spindle poisons including vinca alkaloids such as vinblastine or
  • vincristine or their synthetic analogues such as navelbine, or estramustine or
  • taxoids such as etoposide or teniposide
  • epidophylloptoxins such as etoposide or teniposide
  • antibiotics such as
  • topoisomerase inhibitors such as camptothecin derivatives
  • growth factor inhibitors such as interferons or interleukins.
  • haematopoietic type such as G-CSF or GM-CSF or certain interleukins with
  • Taxol Taxotere, their analogues or their combinations with other therapeutically
  • the invention relates to combinations of taxol, Taxotere
  • This efficacy may be quantified, for example, by the log 10 cells killed, which is
  • the efficacy of the combinations on solid tumors may be determined
  • mice The animals subjected to the experiment, generally mice.
  • tumors are mixed before being subjected to the various treatments and controls.
  • tumors are treated before being subjected to the various treatments and controls.
  • tumors are treated before being subjected to the various treatments and controls.
  • the selected animals are distributed at
  • Chemotherapy generally begins from 3 to 22 days after grafting,
  • the tumors are measured 2 or 3 times a week until the tumor reaches
  • the antitumor activity is determined in accordance with the different conditions
  • the antitumour activity is determined by the
  • chemotherapeutic agents such as cyclophosphamide (alkylating agent), 5-
  • fluorouracil antimetabolite
  • etoposide semisynthetic podophyllotoxin agent
  • vincristine vinca alkaloid
  • debenzoyl-N-t-butoxy-carbonyl-7-deoxy-8-desmethyl-7, 8-cyclopropataxotere (hereinafter acetocyclopropyl taxotere) with several chemotherapeutic agents.
  • agents such as doxorubicin (antibiotic), cisplatin (platinum coordination
  • mice bearing s.c. transplantable tumors were evaluated in mice bearing s.c. transplantable tumors.
  • the tumor model
  • CTI CTI index
  • CTl represents the sum of the fractions of the lethal dose 10% (LD 10 )
  • a CTl of 1 indicates that only 50% of the LD 10
  • each single agent (or any of the ratios, 70:30, 40:60, etc ). can be used in
  • acetocyclopropyl taxotere had a log cell kill of 2.9 and doxorubicin-3.0.
  • HNTD of each single agent can be combined without additional toxicity.
  • mice were not
  • CTl of 0.6 indicates an important overlap in host toxicity.
  • the present invention also relates, therefore, to pharmaceutical compositions containing the combinations according to the invention.
  • the constituents of which the combination are composed may be any constituents of which the combination are composed.
  • compositions according to the invention are preferably compositions
  • compositions which can be administered parentally.
  • these compositions may be any compositions which can be administered parentally.
  • these compositions may be any compositions which can be administered parentally.
  • these compositions may be any compositions which can be administered parentally.
  • compositions for parental administration are generally
  • non-aqueous solutions or suspensions natural vegetable oils such as olive oil,
  • sesame oil or liquid petroleum or injectable organic esters such as ethyl oleate
  • the sterile aqueous solutions can consist of a solution of the
  • aqueous solutions are suitable for intravenous
  • isotonic for example with a sufficient amount of sodium chloride or glucose.
  • sterilization may be carried out by heating or by any other means which does not
  • the combinations may also take the form of
  • liposomes or the form of an association with carriers as cyclodextrins or
  • compositions for oral or intraperitoneal administration are preferably
  • the combinations according to the invention are especially useful in the treatment of cancers of the colon, breast, ovary or lung, as well as melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PCT/IB2002/000853 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives Ceased WO2002074289A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP2002572997A JP4467885B2 (ja) 2001-03-21 2002-03-21 タキサン誘導体を含有する抗腫瘍組成物
EP02713093A EP1478355B1 (en) 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives
CA2440160A CA2440160C (en) 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives
DK02713093T DK1478355T3 (da) 2001-03-21 2002-03-21 Antitumorsammensætninger, som indeholder taxanderivater
AU2002244877A AU2002244877B2 (en) 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives
SI200230525T SI1478355T1 (sl) 2001-03-21 2002-03-21 Protitumorni sestavki, ki vsebujejo taksanske derivate
MXPA03008539A MXPA03008539A (es) 2001-03-21 2002-03-21 Composiciones antitumor que contienen derivados de taxano.
EA200301047A EA006878B1 (ru) 2001-03-21 2002-03-21 Противоопухолевые составы, содержащие производные таксанов
DE60218751T DE60218751T2 (de) 2001-03-21 2002-03-21 Antitumor-zusammensetzungen enthaltend taxan-derivate
BR0208274-8A BR0208274A (pt) 2001-03-21 2002-03-21 Composições antitumorais contendo derivados de taxano
HU0500478A HUP0500478A2 (hu) 2001-03-21 2002-03-21 Taxánszármazékokat tartalmazó tumorellenes készítmények
IL157992A IL157992A (en) 2001-03-21 2003-09-18 Pharmacological preparations containing Texas
CY20071100643T CY1106582T1 (el) 2001-03-21 2007-05-10 Αντικαρκινικες συνθεσεις που περιεχουν παραγωγα ταξανης

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/813,018 US6441026B1 (en) 1993-11-08 2001-03-21 Antitumor compositions containing taxane derivatives
US09/813,018 2001-03-21

Publications (2)

Publication Number Publication Date
WO2002074289A2 true WO2002074289A2 (en) 2002-09-26
WO2002074289A3 WO2002074289A3 (en) 2004-09-02

Family

ID=25211230

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2002/000853 Ceased WO2002074289A2 (en) 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives
PCT/IB2002/002239 Ceased WO2002074232A2 (en) 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/002239 Ceased WO2002074232A2 (en) 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives

Country Status (19)

Country Link
US (1) US6441026B1 (https=)
EP (1) EP1478355B1 (https=)
JP (1) JP4467885B2 (https=)
CN (2) CN101590057A (https=)
AT (1) ATE355837T1 (https=)
AU (1) AU2002244877B2 (https=)
BR (1) BR0208274A (https=)
CA (1) CA2440160C (https=)
CY (1) CY1106582T1 (https=)
DE (1) DE60218751T2 (https=)
DK (1) DK1478355T3 (https=)
EA (1) EA006878B1 (https=)
ES (1) ES2282400T3 (https=)
HU (1) HUP0500478A2 (https=)
IL (1) IL157992A (https=)
MX (1) MXPA03008539A (https=)
PT (1) PT1478355E (https=)
SI (1) SI1478355T1 (https=)
WO (2) WO2002074289A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
BR0310026A (pt) * 2002-05-17 2005-02-15 Aventis Pharma Sa Uso de docetaxel/doxorrubicina/ciclofosfamida em terapia adjuvante de câncer de mama e ovariano
AU2003287081A1 (en) * 2002-10-16 2004-05-04 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
ITMI20030317A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
AU2003239511A1 (en) * 2003-05-20 2004-12-13 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
CN100340296C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 一种抗癌体内植入剂
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
CA2631704A1 (en) 2005-12-05 2007-06-14 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
EP1913958B1 (en) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN101674852A (zh) * 2007-04-10 2010-03-17 日东电工株式会社 多功能聚谷氨酸盐药物载体
CA2683590A1 (en) * 2007-05-09 2008-11-20 Nitto Denko Corporation Compositions that include a hydrophobic compound and a polyamino acid conjugate
CN101707869A (zh) * 2007-05-09 2010-05-12 日东电工株式会社 具有多种药物的聚谷氨酸盐结合物和聚谷氨酸盐-氨基酸结合物
JP2010528122A (ja) * 2007-05-09 2010-08-19 日東電工株式会社 白金薬剤と結合されたポリマー
WO2009111271A1 (en) * 2008-03-06 2009-09-11 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
KR20130140032A (ko) * 2010-11-12 2013-12-23 엔도사이트, 인코포레이티드 암을 치료하는 방법들
CN102241648B (zh) * 2011-01-31 2016-08-03 沈阳东星医药科技有限公司 抗多药耐药紫杉烷类衍生物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253738A1 (fr) 1986-07-17 1988-01-20 Rhone-Poulenc Sante Dérivés du taxol, leur préparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
US4876399A (en) 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US5015744A (en) 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
US5136060A (en) 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
WO1992019765A1 (en) 1991-05-08 1992-11-12 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer
US5229526A (en) 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5284865A (en) 1991-09-23 1994-02-08 Holton Robert A Cyclohexyl substituted taxanes and pharmaceutical compositions containing them
US5262409A (en) 1991-10-11 1993-11-16 Fred Hutchinson Cancer Research Center Binary tumor therapy
US5294737A (en) 1992-02-27 1994-03-15 The Research Foundation State University Of New York Process for the production of chiral hydroxy-β-lactams and hydroxyamino acids derived therefrom
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
EP0982028A1 (en) * 1998-08-20 2000-03-01 Aventis Pharma S.A. New use of taxoid derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253738A1 (fr) 1986-07-17 1988-01-20 Rhone-Poulenc Sante Dérivés du taxol, leur préparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
SI1478355T1 (sl) 2007-08-31
AU2002244877B2 (en) 2006-07-20
WO2002074232A2 (en) 2002-09-26
US20020031505A1 (en) 2002-03-14
CN1536995A (zh) 2004-10-13
CY1106582T1 (el) 2012-01-25
US6441026B1 (en) 2002-08-27
EP1478355A2 (en) 2004-11-24
CA2440160C (en) 2011-07-05
EA200301047A1 (ru) 2004-06-24
PT1478355E (pt) 2007-05-31
BR0208274A (pt) 2004-07-13
WO2002074289A3 (en) 2004-09-02
ATE355837T1 (de) 2007-03-15
HUP0500478A2 (hu) 2005-08-29
CA2440160A1 (en) 2002-09-26
JP2004536790A (ja) 2004-12-09
JP4467885B2 (ja) 2010-05-26
EA006878B1 (ru) 2006-04-28
EP1478355B1 (en) 2007-03-07
CN101590057A (zh) 2009-12-02
ES2282400T3 (es) 2007-10-16
IL157992A (en) 2008-08-07
DK1478355T3 (da) 2007-07-02
DE60218751D1 (de) 2007-04-19
MXPA03008539A (es) 2004-08-11
DE60218751T2 (de) 2007-11-22

Similar Documents

Publication Publication Date Title
US5908835A (en) Anti-tumor compositions containing taxane derivatives
US6441026B1 (en) Antitumor compositions containing taxane derivatives
AU2002244877A1 (en) Antitumor compositions containing taxane derivatives
EP1977753A1 (en) Combined preparation comprising anthracycline derivatives
Saotome et al. Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma
Kelly Irinotecan in small-cell lung cancer: current data
HK1138185A (en) Antitumor compositions containing taxane derivatives
HK1096867A (en) Combined preparations comprising anthracycline derivatives
HK1096538A (en) Combined preparations comprising anthracycline derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2440160

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002244877

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002713093

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 157992

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/008539

Country of ref document: MX

Ref document number: 028068572

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002572997

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1290/KOLNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200301047

Country of ref document: EA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002713093

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002713093

Country of ref document: EP